Erratum: Molecular screening for familial hypercholesterolaemia: consequences for life and disability insurance (European Journal of Human Genetics (2007) 10.1038/sj.ejhg.5201940);Molecular screening for familial hypercholesterolaemia: Consequences for life and disability insurance

European Journal of Human Genetics

Volumn 16, Issue 1, 2008, Pages 14-17

  Homsma, Sietske J M ^a   Huijgen, Roeland ^b   Middeldorp, Saskia ^b   Sijbrands, Eric J G ^c   Kastelein, John J P ^b  

^a General Medical Affairs   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; DNA; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN RECEPTOR;

ACCESS TO INFORMATION; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTRACT; DNA DETERMINATION; FAMILIAL HYPERCHOLESTEROLEMIA; GENE MUTATION; GENETIC RISK; GENETIC SCREENING; HETEROZYGOTE DETECTION; HUMAN; INSURANCE; LEGAL ASPECT; MASS SCREENING; MORBIDITY; MORTALITY; NETHERLANDS; PHENOTYPE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR;

EID: 37249037439     PISSN: 10184813     EISSN: 14765438     Source Type: Journal    
DOI: 10.1038/sj.ejhg.5201972     Document Type: Erratum

References (27)

1. Scientific Steering Committee on behalf of the Simon Broome Register Group: Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management. Atherosclerosis 1999; 142 105-112.
2. Goldstein JL, Hobbs HH, Brown MS: The Metabolic and Molecular Bases of Inherited Disease. New York: McGraw-Hill, 2001.
3. Marks D, Thorogood M, Nell HA, Humphries SE: A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia. Atherosclerosis 2003; 168: 1-14.
4. Lansberg PJ, Tuzgol S, van de Ree MA, Defesche JC, Kastelein JJ: Higher prevalence of familial hypercholesterolemia than expected in adult patients of four family practices, in Netherlands. Ned Tijdschr Geneeskd 2000; 144: 1437-1440.
5. Godard B, Raeburn S, Pembrey M, Bobrow M, Farndon P, Ayme S: Genetic information and testing in insurance and employment: Technical, social and ethical issues. Eur J Hum Genet 2003; 11 (Suppl 2): S123- S142.
6. Hadfield SG, Humphries SE: Implementation of cascade testing for the detection of familial hypercholesterolaemia. Curr Opin Lipidol 2005; 16: 428-433.
7. Josefson D: Clinton outlaws genetic discrimination in federal jobs. BMJ 2000; 320: 468.
8. Low L, King S, Wilkie T. Genetic discrimination in life insurance: empirical evidence from a cross sectional survey of genetic support groups in the United Kingdom. BMJ 1998; 317: 1632-1635.
9. Newson AJ, Humphries SE: Cascade testing in familial hypercholesterolaemia: How should family members be contacted? Eur J Hum Genet 2005; 13: 401-408.
10. Raithatha N, Smith RD: Disclosure of genetic tests for health insurance: is it ethical not to? Lancet 2004; 363: 395-396.
11. Defesche JC: Familial bypercholesterolemia. In Betteridge DJ (ed): Lipids and Vascular Disease. London: Martin Dunitz Ltd, 2000, pp 65-76.
12. Umans-Eckenhausen MA, Defesche JC, Sijbrands EJ, Scheerder RL, Kastelein JJ: Review of first 5 years of screening for familial hypercholesterolaemia in The Netherlands. Lancet 2001; 357: 165-168.
13. Medical Examination Act. Journal of the State (in Dutch) 1997; 636-642.
14. Goedvolk VI: The MedicaP Examination Act: practical experience from The Netherlands. International Conference on Genetics and Private Life/ Health Insurance 1999, February 11.
15. Marang-van de Mheen PJ, van Maarle MC, Stouthard ME: Getting insurance after genetic screening on familial hypercholesterolaemia; the need to educate both insurers and the public to increase adherence to national guidelines in The Netherlands. J Epidemiol Community Health 2002; 56: 145-147.
16. ten Asbroek AH, de Mheen PJ, Defesche JC, Kastelein JJ, Gunning-Schepers LJ: Results from a family and DNA based active identification programme for familial hypercholesterolaemia. J Epidemiol Community Health 2001; 55: 500-502.
17. Dutch Health Council: Familial Hypercholesterolaemia and the Medical Examination Act. Publications of the Dutch Health Council (in Dutch) 2001; 1-56.
18. Baigent C, Keech A, Kearney PM et al: Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-1278.
19. Packard C: A triumvirate of targets in the prevention and treatment paradigm for cardiovascular disease. Atheroscler Suppl 2006; 7 21-29.
20. de Sauvage Nolting PR, Buirma RJ, Hutten BA, Kastelein JJ: Two-year efficacy and safety of simvastatin 80mg in familial hypercholesterolemia (the Examination of Probands and Relatives in Statin Studies With Familial hypercholesterolemia [ExPRESS fh]). Am J Cardiol 2002; 90: 181-184.
21. Smilde TJ, van WS, Wollersheim H, Trip MD, Kastelein JJ, Stalenhoef AF: Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): A prospective, randomised, double-blind trial. Lancet 2001; 357 577-581.
22. Damgaard D, Larsen ML, Nissen PH et al: The relationship of molecular genetic to clinical diagnosis of familial hypercholesterolemia in a Danish population. Atherosclerosis 2005; 180: 155-160.
23. Fouchier SW, Defesche JC, Umans-Eckenhausen MW, Kastelein JP: The molecular basis of familial hypercholesterolemia in The Netherlands. Hum Genet 2001; 109: 602-615.
24. Jansen AC, van Aalst-Cohen ES, Tanck MW et al: The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: Data in 2400 patients. J Intern Med 2004; 256: 482-490.
25. Sijbrands EJ, Westendorp RG, Defesche JC, de Meier PH, Smelt AH, Kastelein JJ: Mortality over two centuries in large pedigree with familial hypercholesterolaemia: Family tree mortality study. BMJ 2001; 322: 1019-1023.
26. Umans-Eckenhausen MA, Sijbrands EJ, Kastelein JJ, Defesche JC: Low-density lipoprotein receptor gene mutations and cardiovascular risk in a large genetic cascade screening population. Circulation 2002; 106: 3031-3036.
27. Association of Insurers: Familial Hypercholesterolemia (FH) and Insurance (in Dutch). The Hague: Publication by the Dutch Association of Insurers, 2003.